Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study

@article{Apostol2011EfficacyAS,
  title={Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study},
  author={George Apostol and W. Abi-Saab and C. Kratochvil and L. Adler and W. Robieson and Laura M. Gault and Y. Pritchett and D. Feifel and M. Collins and M. Saltarelli},
  journal={Psychopharmacology},
  year={2011},
  volume={219},
  pages={715-725}
}
Rationaleα4β2 Neuronal nicotinic receptors (NNRs) are implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD).ObjectivesThis study examined the efficacy and safety of the α4β2 NNR partial agonist ABT-089 versus placebo in adults with ADHD.MethodsIn this multicenter, randomized, double-blind, placebo-controlled crossover study, subjects received placebo followed by ABT-089 (2 mg once daily [QD], 5 mg QD, 15 mg QD, 40 mg QD, or 40 mg twice daily [BID]), or vice versa… Expand
43 Citations

Paper Mentions

Interventional Clinical Trial
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.  
ConditionsAttention-Deficit/Hyperactivity Disorder
InterventionDrug
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD
  • 41
  • PDF
The α7 Nicotinic Receptor Agonist ABT-107 Decreases l-Dopa–Induced Dyskinesias in Parkinsonian Monkeys
  • 25
  • PDF
Agonist and antagonist effects of cytisine in vivo
  • 11
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study
  • 110
Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.
  • 29
A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder.
  • 215
  • Highly Influential
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
  • 180
  • PDF
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
  • 523
Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity Disorder: A 6-Month, Double-Blind Trial
  • 131
Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder.
  • 70
  • Highly Influential
Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition.
  • 131
  • Highly Influential
...
1
2
3
4
5
...